GlassScriptPhysician profile
Antwan Atia
NPI 1487820353
$8,897.90
in general payments reported to CMS, 2019-2025
27 companies · $942 in 2025
The $942 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $221 · 2021: $907 · 2022: $4,280 · 2023: $778 · 2024: $647 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,900.27 | 2021-2025 | Interstim |
| Abbvie INC. | $2,333.25 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Gilead Sciences, INC. | $510.20 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $475.34 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $260.29 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $212.40 | 2019-2021 | |
| Boston Scientific Corporation | $149.50 | 2022 | |
| Pfizer INC. | $147.88 | 2019-2025 | |
| Genzyme Corporation | $143.55 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $118.06 | 2019-2024 | Linzess |
| Qol Medical, LLC | $106.32 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $92.33 | 2022-2025 | Dupixent |
| Celgene Corporation | $86.96 | 2022 | |
| Braintree Laboratories, INC. | $61.74 | 2019-2024 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $47.52 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $40.46 | 2019 | |
| Intercept Pharmaceuticals, INC. | $35.02 | 2019-2021 | |
| Daiichi Sankyo INC. | $30.08 | 2021 | |
| Shire North American Group INC | $27.35 | 2019 | |
| Nestle Healthcare Nutrition INC. | $21.71 | 2022 | |
| Romark Laboratories, Lc | $17.23 | 2019 | |
| Ucb, INC. | $15.55 | 2019 | |
| Capsovision, INC. | $13.71 | 2024 | Capsocam Plus |
| Phadia US INC. | $13.64 | 2022 | |
| Ardelyx, INC. | $13.00 | 2022 | |
| Covidien LP | $12.79 | 2019 | |
| Shionogi INC | $11.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antwan Atia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.